Global Peptic Ulcers Market

Global Peptic Ulcers Market Insights Forecasts to 2035

• The Global Peptic Ulcers Market Size Was valued at USD 4.9 Billion in 2024
• The Global Peptic Ulcers Market Size is Expected to Grow at a CAGR of around 2.89% from 2025 to 2035
• The Worldwide Peptic Ulcers Market Size is Expected to Reach USD 6.7 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

 

 

According to a research report published by Decisions Advisors and Consulting, the Global Peptic Ulcers Market size was worth around USD 4.9 Billion in 2024 and is predicted to grow to around USD 6.7 Billion by 2035 with a compound annual growth rate (CAGR) of 2.89% from 2025 to 2035. The market shows strong potential for future growth because of increasing demand for acid-suppression therapies and rising H. pylori cases and growing availability of generic drugs and telemedicine services and the expansion of over-the-counter products and new biologic treatments and enhanced diagnostic methods and healthcare development in emerging markets.

 

Market Overview

The global peptic ulcers market refers to the worldwide industry which handles all aspects of peptic ulcer disease including its diagnosis and treatment and patient management. The market includes drug therapies such as proton pump inhibitors and H2 receptor antagonists and antibiotics and protective agents together with diagnostic and supportive care solutions. The increasing prevalence of gastrointestinal disorders combined with the needs of elderly people and the dangers arising from their lifestyle choices drives market growth. The governments help the market grow through their financial support of public healthcare programs which include insurance coverage and ulcer education initiatives and early illness detection and treatment programs. The regulatory authorities boost access to affordable treatment options in both developed nations and developing markets by facilitating the approval process for generic medications and clinical research activities.

 

Report Coverage

This research report categorizes the peptic ulcers market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the peptic ulcers market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the peptic ulcers market. 

 

Driving Factors

The global peptic ulcers market growth results from rising gastrointestinal disorder cases and increasing Helicobacter pylori infections and higher NSAID consumption and the growing elderly population and the spread of unhealthy eating patterns. The development of advanced proton pump inhibitors and potassium-competitive acid blockers and targeted antibiotic therapies and minimally invasive endoscopic procedures and AI-based diagnostics and improved drug delivery systems has increased treatment effectiveness and expanded accessibility while driving global market expansion.

 

Restraining Factors

The market expansion and prompt treatment implementation face obstacles because of expensive treatment expenses and growing antibiotic resistance and harmful drug reactions and low-income regions and their people who lack proper medical education and incorrect diagnosis and demanding drug approval processes and their tendency to choose different treatment methods.

 

Market Segmentation

The peptic ulcers market share is classified into treatment type and medication type.

• The proton pump inhibitors (PPIS) segment dominated the market in 2024, approximately 51.1% and is projected to grow at a substantial CAGR during the forecast period.

Based on the treatment type, the peptic ulcers market is divided into proton pump inhibitors (PPIS), h2 antagonists, antibiotics, and others. Among these, the proton pump inhibitors (PPIS) segment dominated the market in 2024, approximately 51.1% and is projected to grow at a substantial CAGR during the forecast period. The medical community uses them as the primary treatment option because they demonstrate effective results when used together with other medications to treat H. pylori infections and their clinical results. The availability of generic medications together with their safe usage and the preference of doctors for specific treatments continues to create persistent demand. The demand for this market continues to grow because doctors show a strong preference for these generic medications which also provide safe treatment options.

 

• The generic drugs segment accounted for the largest share in 2024, approximately 62% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the medication type, the peptic ulcers market is divided into branded medications and generic drugs. Among these, the generic drugs segment accounted for the largest share in 2024, approximately 62% and is anticipated to grow at a significant CAGR during the forecast period. The affordable treatments enable medical facilities to provide care for a vast number of patients who need treatment especially in markets which prioritize cost efficiency and developing regions. The generic market for branded ulcer medications expanded after their patent protection period ended. The healthcare system uses generics because both governments and insurers support this practice to decrease their total spending. The sustained global market leadership of the segment receives additional support from three factors which include equal treatment effectiveness, increased drugstore distribution, and high levels of doctor endorsement.

 

 

 

Regional Segment Analysis of the Peptic Ulcers Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the peptic ulcers market over the predicted timeframe.

North America is anticipated to hold the largest share of the peptic ulcers market over the predicted timeframe. The advanced healthcare system of the country together with its high rates of medical diagnosis and treatment and its presence of major pharmaceutical companies and its accessibility to prescription medications. The market maintains its regional dominance because of reimbursement policies which benefit the industry together with the increasing cases of gastrointestinal disorders and the expanding elderly population and ongoing research activities.

 

Asia-Pacific is expected to grow at a rapid CAGR in the peptic ulcers market during the forecast period. The region experiences market expansion because of its extensive patient base and increasing cases of Helicobacter pylori infections and the development of better healthcare facilities and the growing understanding of health matters. The treatment accessibility improves through expanded insurance coverage and the rise of generic drug production and government healthcare funding and increasing consumer disposable income.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the peptic ulcers market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AstraZeneca
• Takeda Pharmaceutical
• Pfizer Inc.
• GlaxoSmithKline (GSK)
• Eisai Co., Ltd.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Dr. Reddy’s Laboratories
• Cadila Healthcare (Zydus Lifesciences)
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In February 2025, Daewoong Pharmaceutical launched Fexuclue Tablets 20 mg, Korea’s first P-CAB that had been approved to prevent NSAID-induced peptic ulcers. It offered a new preventive option with once-daily dosing and strong clinical evidence, and aimed to expand global applications.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the peptic ulcers market based on the below-mentioned segments: 

 

Global Peptic Ulcers Market, By Treatment Type

• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Antibiotics
• Others

 

Global Peptic Ulcers Market, By Medication Type

• Branded Medications
• Generic Drugs

 

Global Peptic Ulcers Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the projected growth of the global peptic ulcers market by 2035?

A: The market is projected to grow from USD 4.9 billion in 2024 to USD 6.7 billion by 2035, expanding at a CAGR of 2.89% due to treatment demand.

 

2. Which treatment segment leads the peptic ulcers market?

A: Proton pump inhibitors lead the treatment segment, holding 51.1% share in 2024, driven by strong clinical effectiveness, physician preference, combination therapy use, and widespread generic availability.

 

3. Why do generic drugs dominate the medication segment?

A: Generic drugs dominate with a 62% share due to affordability, patent expirations of branded medicines, government and insurer support, comparable therapeutic effectiveness, wider distribution networks, and strong physician acceptance.

 

4. Why does North America lead the regional peptic ulcers market?

A: North America leads due to advanced healthcare systems, high diagnosis rates, strong pharmaceutical presence, favorable reimbursement policies, growing elderly population, increasing gastrointestinal disorders, and continuous medical research investments.

 

5. Why is Asia-Pacific the fastest-growing regional market?

A: Asia-Pacific grows fastest because of large patient populations, rising Helicobacter pylori infections, improving healthcare infrastructure, expanding insurance coverage, increasing generic drug manufacturing, government healthcare spending, and higher disposable incomes.